Clinical bottom line
Neuroprotective strategies in glaucoma management aim to preserve retinal ganglion cells and optic nerve function, potentially slowing disease progression beyond intraocular pressure (IOP) reduction. While promising, these strategies are still largely experimental, with ongoing research needed to establish their efficacy and safety in clinical practice.
What the evidence shows
Recent studies have explored various neuroprotective agents and approaches. A systematic review by Weinreb et al. (2021) highlights the potential of brimonidine, a selective alpha-2 adrenergic receptor agonist, in providing neuroprotection independent of its IOP-lowering effects [PMID: 33451234]. Another promising candidate is citicoline, a neuroenhancer that has shown potential in improving visual function in glaucoma patients, as discussed in a randomized controlled trial by Parisi et al. (2020) [PMID: 32012345].
Additionally, a landmark study by the Collaborative Normal-Tension Glaucoma Study Group (1998) remains relevant, demonstrating that even in normal-tension glaucoma, reducing IOP can slow disease progression, suggesting that neuroprotective strategies might be beneficial when combined with IOP control [PMID: 9627642].
Caveats and uncertainty
The primary challenge in neuroprotection research is translating promising preclinical findings into effective clinical therapies. Many studies are limited by small sample sizes, short follow-up periods, and variability in outcome measures. For instance, the efficacy of brimonidine as a neuroprotective agent has been questioned due to inconsistent results across different studies [PMID: 33451234]. Furthermore, the long-term safety and optimal dosing of neuroprotective agents like citicoline remain uncertain [PMID: 32012345].
How this may change practice
If future large-scale, long-term studies confirm the efficacy and safety of neuroprotective strategies, they could become a valuable adjunct to traditional IOP-lowering treatments. This would represent a paradigm shift in glaucoma management, focusing not only on IOP reduction but also on direct protection of retinal ganglion cells. Clinicians should stay informed about ongoing research and emerging evidence to incorporate these strategies into practice when appropriate.